Resiquimod sulfate

{
  "id": "MLC-T-ONC-016498",
  "term": "Resiquimod sulfate",
  "field": "Oncology and biomedicine",
  "definition": "The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, with potential immunostimulating and antineoplastic activities. Upon administration, resiquimod targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.",
  "synonyms": [
    "toll-like receptor agonist BDB001",
    "TLR7/8 agonist EIK1001",
    "C151008135D",
    "R848 sulfate",
    "TLR agonist BDB001",
    "toll-like receptor 7/8 agonist EIK1001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/resiquimod-sulfate/"
}